Pharmacological Effects and Molecular Protective Mechanisms of Astragalus Polysaccharides on Nonalcoholic Fatty Liver Disease
Authors:
Open Access
- 3 March 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 854674
Abstract
Nonalcoholic fatty liver disease (NAFLD) has been renamed metabolic dysfunction-associated fatty liver disease (MAFLD), a condition for which there is now no authorized treatment. The search for new medications to treat MAFLD made from natural substances is gaining traction. The function of anti-oxidant, anti-inflammation, hypoglycaemic, antiviral, hypolipidemic, and immunomodulatory actions of Astragalus polysaccharides (APS), a chemical molecule isolated from Astragalus membranaceus, has become the focus of therapeutic attention. We have a large number of papers on the pharmacological effects of APS on NAFLD that have never been systematically reviewed before. According to our findings, APS may help to slow the progression of non-alcoholic fatty liver disease (NAFL) to non-alcoholic steatohepatitis (NASH). Lipid metabolism, insulin resistance (IR), oxidative stress (OS), endoplasmic reticulum stress (ERS), inflammation, fibrosis, autophagy, and apoptosis are some of the pathogenic pathways involved. SIRT1/PPARα/FGF21, PI3K/AKT/IRS-1, AMPK/ACC, mTOR/4EBP-1/S6K1, GRP78/IRE-1/JNK, AMPK/PGC-1/NRF1, TLR4/MyD88/NF-κB, and TGF-β/Smad pathways were the most common molecular protective mechanisms. All of the information presented in this review suggests that APS is a natural medication with a lot of promise for NAFLD, but more study, bioavailability studies, medicine type and dosage, and clinical proof are needed. This review could be useful for basic research, pharmacological development, and therapeutic applications of APS in the management of MAFLD.Keywords
This publication has 80 references indexed in Scilit:
- The role of quantitative changes in the epxression of insulin receptor substrate-1 and nuclear ubiquitin in abnormal glycometabolism in the livers of KKay mice and the relative therapeutic mechanisms of Astragalus polysaccharideInternational Journal of Molecular Medicine, 2013
- Decoding cell death signals in liver inflammationJournal of Hepatology, 2013
- Notch Signal Suppresses Toll-like Receptor-triggered Inflammatory Responses in Macrophages by Inhibiting Extracellular Signal-regulated Kinase 1/2-mediated Nuclear Factor κB ActivationJournal of Biological Chemistry, 2012
- Astragalus Polysaccharides Lowers Plasma Cholesterol through Mechanisms Distinct from StatinsPLOS ONE, 2011
- Oxysterols as biomarkers in neurodegenerative diseasesChemistry and Physics of Lipids, 2011
- A position statement on NAFLD/NASH based on the EASL 2009 special conferenceJournal of Hepatology, 2010
- The Role of PPARActivation in Liver and MusclePPAR Research, 2010
- Astragalus polysaccharides alleviates glucose toxicity and restores glucose homeostasis in diabetic states via activation of AMPKActa Pharmacologica Sinica, 2009
- Astragalus polysaccharides decreased the expression of PTP1B through relieving ER stress induced activation of ATF6 in a rat model of type 2 diabetesMolecular and Cellular Endocrinology, 2009
- ROS, mitochondria and the regulation of autophagyTrends in Cell Biology, 2007